chaetoglobosin D | 55945-73-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: chaetoglobosin D
• 英文别名: (1R,3E,6R,7E,9S,11E,13R,14S,16S,17R,18S)-6,14-dihydroxy-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-15-methylidene-19-azatricyclo[11.7.0.01,17]icosa-3,7,11-triene-2,5,20-trione
• CAS: 55945-73-8
• 化学式: C₃₂H₃₆N₂O₅
• 分子量: 528.648
• InChiKey: FTBNYQWFSWKCKW-WHHLLCSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  39
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  chaetoglobosin D 在 三乙胺 作用下， 以 吡啶 为溶剂， 生成 Acetic acid (7E,11E)-(1R,9S,13R,14S,16S,17R,18S)-18-(1H-indol-3-ylmethyl)-7,9,16-trimethyl-15-methylene-2,5,6,20-tetraoxo-19-aza-tricyclo[11.7.0.0^1,17]icosa-7,11-dien-14-yl ester
  参考文献：
  名称：

  Chaetoglobosins, cytotoxic 10-(indol-3-yl)-(13)cytochalasans from Chaetomium spp. III. Structures of chaetoglobosins C, E, F, G, and J.

  摘要：

  根据物理数据，特别是1H-NMR和化学相关性，确定了chaetoglobosins C、E、F、G和J（10-(吲哚-3-基)-[13]细胞色素）的结构（图1）。本文讨论了chaetoglobosins的立体结构特征。

  DOI：

  10.1248/cpb.30.1629
• 作为产物：
  描述：

  毛壳球菌素 在 三氟化硼乙醚 作用下， 反应 0.08h， 以7 mg的产率得到chaetoglobosin B
  参考文献：
  名称：

  Chaetoglobosins, cytotoxic 10-(indo-3-yl)-(13)cytochalasans from Chaetomium spp. II. Structures of chaetoglobosins A, B, and D.

  摘要：

  通过异构化反应和物理方法（包括精确的 1H-NMR 解偶联实验），阐明了 10-（吲哚-3-基）-[13] 环荼蘼素（Chaetoglobosins A、B 和 D）的结构（图 7）。

  DOI：

  10.1248/cpb.30.1618

文献信息

• Intravascular stent with cytoskeletal inhibitors for the prevention of restenosis
  申请人：Boston Scientific Limited

  公开号：EP1512398A1

  公开（公告）日：2005-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2098230A1

  公开（公告）日：2009-09-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Therapeutic inhibitors of vascular smooth muscle cells
  申请人：Boston Scientific Limited

  公开号：EP2298310A2

  公开（公告）日：2011-03-23

  Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

  本发明提供了抑制哺乳动物宿主血管创伤或疾病后狭窄的方法，包括向宿主施用治疗有效剂量的治疗共轭物，该共轭物含有血管平滑肌结合蛋白，该蛋白以特定方式与血管平滑肌细胞的细胞表面结合，并与抑制肌肉细胞的细胞活性的治疗剂剂型耦合。还提供了向血管平滑肌细胞直接和/或靶向输送治疗剂的方法，这种方法通过抑制平滑肌细胞收缩，使血管腔扩张和固定，从而构成生物支架。
• Dosage form comprising taxol in crystalline form
  申请人：BOSTON SCIENTIFIC SCIMED LIMITED

  公开号：EP2292225A1

  公开（公告）日：2011-03-09

  Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

  提供了抑制哺乳动物宿主血管创伤后狭窄或再狭窄的方法，包括向宿主施用治疗有效剂量的细胞抑制剂和/或细胞骨架抑制剂，以便对创伤血管进行生物支架治疗。还提供了一种抑制或减少血管创伤后血管重塑的方法，包括施用有效量的细胞骨架抑制剂。还提供了包含本发明治疗剂的药物组合物和试剂盒。
• Molybdenum alloys for medical devices
  申请人：MIRUS

  公开号：US10682437B2

  公开（公告）日：2020-06-16

  A medical device having improved surface hardness and wear resistance properties. The medical device has a body that includes a molybdenum and rhenium alloy. The outer surface of the body has a nitride surface layer that includes nitrogen, molybdenum and rhenium.

  一种具有更高的表面硬度和耐磨性能的医疗器械。该医疗器械的主体包括钼和铼合金。主体的外表面有一个氮化物表面层，其中包括氮、钼和铼。